These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

765 related articles for article (PubMed ID: 25483833)

  • 1. The role of diffusion-weighted MRI and (18)F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: a systematic review.
    Joye I; Deroose CM; Vandecaveye V; Haustermans K
    Radiother Oncol; 2014 Nov; 113(2):158-65. PubMed ID: 25483833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline and early digital [ 18 F]FDG PET/CT and multiparametric MRI contain promising features to predict response to neoadjuvant therapy in locally advanced rectal cancer patients: a pilot study.
    Vuijk FA; Feshtali Shahbazi S; Noortman WA; van Velden FHP; Dibbets-Schneider P; Marinelli AWKS; Neijenhuis PA; Schmitz R; Ghariq E; Velema LA; Peters FP; Smit F; Peeters KCMJ; Temmink SJD; Crobach SALP; Putter H; Vahrmeijer AL; Hilling DE; de Geus-Oei LF
    Nucl Med Commun; 2023 Jul; 44(7):613-621. PubMed ID: 37132268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDG-avid presacral soft tissue mass in previously treated rectal cancer: Diagnostic outcome and additional value of MRI, including diffusion-weighted imaging.
    Pennings JP; de Haas RJ; Murshid KJA; de Jong KP; Dierckx RAJO; Kwee TC
    Eur J Surg Oncol; 2019 Apr; 45(4):606-612. PubMed ID: 30594404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The predictive value of 18F-FDG PET/CT for assessing pathological response and survival in locally advanced rectal cancer after neoadjuvant radiochemotherapy.
    Leccisotti L; Gambacorta MA; de Waure C; Stefanelli A; Barbaro B; Vecchio FM; Coco C; Persiani R; Crucitti A; Tortorelli AP; Giordano A; Valentini V
    Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):657-66. PubMed ID: 25687534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is diffusion-weighted MRI superior to FDG-PET or FDG-PET/CT in evaluating and predicting pathological response to preoperative neoadjuvant therapy in patients with rectal cancer?
    Li YL; Wu LM; Chen XX; Delproposto Z; Hu JN; Xu JR
    J Dig Dis; 2014 Oct; 15(10):525-37. PubMed ID: 25060294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative imaging outperforms molecular markers when predicting response to chemoradiotherapy for rectal cancer.
    Joye I; Debucquoy A; Deroose CM; Vandecaveye V; Cutsem EV; Wolthuis A; D'Hoore A; Sagaert X; Zhou M; Gevaert O; Haustermans K
    Radiother Oncol; 2017 Jul; 124(1):104-109. PubMed ID: 28647399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early prediction of response by ¹⁸F-FDG PET/CT during preoperative therapy in locally advanced rectal cancer: a systematic review.
    Maffione AM; Chondrogiannis S; Capirci C; Galeotti F; Fornasiero A; Crepaldi G; Grassetto G; Rampin L; Marzola MC; Rubello D
    Eur J Surg Oncol; 2014 Oct; 40(10):1186-94. PubMed ID: 25060221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of diffusion-weighted imaging in the detection of viable tumour after neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer: comparison with T2 weighted and PET/CT imaging.
    Song I; Kim SH; Lee SJ; Choi JY; Kim MJ; Rhim H
    Br J Radiol; 2012 May; 85(1013):577-86. PubMed ID: 21343320
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Avallone A; Aloj L; Pecori B; Caracò C; De Stefano A; Tatangelo F; Silvestro L; Granata V; Bianco F; Romano C; Di Gennaro F; Budillon A; Petrillo A; Muto P; Botti G; Delrio P; Lastoria S
    J Nucl Med; 2019 Nov; 60(11):1560-1568. PubMed ID: 30877175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffusion-weighted MRI and
    Xu X; Sun ZY; Wu HW; Zhang CP; Hu B; Rong L; Chen HY; Xie HY; Wang YM; Lin HP; Bai YR; Ye Q; Ma XM
    Radiat Oncol; 2021 Jul; 16(1):132. PubMed ID: 34281566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early prediction of histopathological response of rectal tumors after one week of preoperative radiochemotherapy using 18 F-FDG PET-CT imaging. A prospective clinical study.
    Goldberg N; Kundel Y; Purim O; Bernstine H; Gordon N; Morgenstern S; Idelevich E; Wasserberg N; Sulkes A; Groshar D; Brenner B
    Radiat Oncol; 2012 Aug; 7():124. PubMed ID: 22853868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of diffusion-weighted magnetic resonance imaging for prediction and early assessment of response to neoadjuvant radiochemotherapy in rectal cancer: preliminary results.
    Lambrecht M; Vandecaveye V; De Keyzer F; Roels S; Penninckx F; Van Cutsem E; Filip C; Haustermans K
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):863-70. PubMed ID: 21398048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy.
    Ohno Y; Koyama H; Yoshikawa T; Matsumoto K; Aoyama N; Onishi Y; Sugimura K
    AJR Am J Roentgenol; 2012 Jan; 198(1):75-82. PubMed ID: 22194481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential predictive value of MRI and PET-CT in mucinous and nonmucinous rectal cancer to identify patients at high risk of metastatic disease.
    Barbaro B; Leccisotti L; Vecchio FM; Di Matteo M; Serra T; Salsano M; Poscia A; Coco C; Persiani R; Alfieri S; Gambacorta MA; Valentini V; Giordano A; Bonomo L
    Br J Radiol; 2017 Jan; 90(1069):20150836. PubMed ID: 27845566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Diffusion-Weighted Imaging and
    Noij DP; Martens RM; Koopman T; Hoekstra OS; Comans EFI; Zwezerijnen B; de Bree R; de Graaf P; Castelijns JA
    Clin Oncol (R Coll Radiol); 2018 Dec; 30(12):780-792. PubMed ID: 30318343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging.
    Heusner TA; Kuemmel S; Koeninger A; Hamami ME; Hahn S; Quinsten A; Bockisch A; Forsting M; Lauenstein T; Antoch G; Stahl A
    Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1077-86. PubMed ID: 20204355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of 18F-FDG PET/CT for assessing the response to neoadjuvant therapy in locally advanced rectal cancer.
    Murcia Duréndez MJ; Frutos Esteban L; Luján J; Frutos MD; Valero G; Navarro Fernández JL; Mohamed Salem L; Ruiz Merino G; Claver Valderas MA
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):91-7. PubMed ID: 23081822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of combined multiparametric MRI and FDG-PET/CT to identify well-responding rectal cancer patients before the start of neoadjuvant chemoradiation.
    Schurink NW; Min LA; Berbee M; van Elmpt W; van Griethuysen JJM; Bakers FCH; Roberti S; van Kranen SR; Lahaye MJ; Maas M; Beets GL; Beets-Tan RGH; Lambregts DMJ
    Eur Radiol; 2020 May; 30(5):2945-2954. PubMed ID: 32034488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of diffusion-weighted MR imaging and FDG PET/CT to predict pathological complete response to neoadjuvant chemotherapy in patients with breast cancer.
    Park SH; Moon WK; Cho N; Chang JM; Im SA; Park IA; Kang KW; Han W; Noh DY
    Eur Radiol; 2012 Jan; 22(1):18-25. PubMed ID: 21845462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.